Lupin Ltd Receives Tentative US FDA Approval for Novel Apixaban Oral Suspension

Key numbers

Market Cap	₹95,665.07 CrLarge Cap
TTM Net Profit	₹5,528.81 CrTrailing 12 Months
PE TTM	17.3Sector PE 50.35
ROE Annual	23.75%Return on Equity
Order from	U.S. Food and Drug Administration (U.S. FDA)

Key highlights

• Approval granted for Apixaban Oral Suspension 1.25mg/mL via the 505(b)(2) pathway
• Product serves as a liquid alternative to Eliquis (apixaban) by Bristol Myers Squibb
• Manufacturing slated for Lupin's state-of-the-art facility in Somerset, New Jersey
• Lupin maintains a TTM net profit of 5528.81 crore with a 23.75 percent Annual ROE
• The company operates 15 manufacturing facilities and 6 research centers globally

What Approval Was Received?

Lupin has secured tentative approval from the U.S. Food and Drug Administration for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL. This specific formulation was developed through the 505(b)(2) pathway, which allows for the approval of a new drug that relies on at least some of the information from a previously approved drug.

The product is a liquid version of the widely prescribed anticoagulant Eliquis, designed to facilitate easier administration for patients who have difficulty swallowing solid dosage forms. While the approval is currently tentative, it confirms that the drug meets the required safety and efficacy standards for eventual commercial distribution.

Commercial Significance and Patient Impact

• Targets adult patients needing anticoagulation therapy who face barriers with traditional tablet forms
• Expands the company's portfolio of differentiated medicines in the cardiovascular therapeutic area
• Utilizes U.S.-based manufacturing expertise at the Somerset facility to ensure high-quality supply standards
• Positions Lupin to capture market share in a segment currently dominated by branded tablet formulations
• Reinforces the company's focus on complex generics and specialty medicine development

Strategic Manufacturing Hub

Upon receiving final approval, the Apixaban Oral Suspension will be manufactured at Lupin's Somerset facility in New Jersey. This move highlights the company's strategic investment in U.S.-based production to support its domestic operations and ensure supply chain reliability for the American market. The facility is equipped to handle complex liquid formulations, aligning with the company's broader objective to build a differentiated product portfolio.

Lupin's global infrastructure currently supports distribution in over 100 markets, backed by a dedicated workforce of over 26,000 professionals and a strong presence in both the U.S. and Indian pharmaceutical landscapes.

Financial Performance and Sector Position

Lupin currently trades at a TTM Price-to-Earnings (PE) ratio of 17.3, which stands in contrast to the industry PE of 48.32 and the broader sector PE of 50.35. The company's annual revenue growth reached 23.92 percent, with a net profit annual growth of 62.51 percent. This regulatory milestone comes at a time when Lupin has demonstrated consistent operational efficiency, evidenced by an annual net profit of 5332.84 crore and a robust Piotroski Score of 7.

The company's diversified portfolio across generic and specialty medicines continues to drive revenue, with TTM operating revenue reaching 29,966.58 crore.

Management Perspective on Differentiated Medicines

This tentative approval reflects our continued focus on developing differentiated medicines that address meaningful patient needs. Apixaban oral suspension expands the ways in which this important therapy could be administered, while reinforcing our commitment to building a differentiated portfolio.

Lupin · financial snapshot

Share price	₹2092
Market capitalisation	₹95,665.07 Cr
Revenue (annual)	₹27,958.03 Cr
Net profit (annual)	₹5,332.84 Cr
P/E (TTM)	17.3×Sector 50.35×
Promoter holding	46.85%-0.01% QoQ
FII holding	22.42%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.